HOOK Logo

HOOKIPA Pharma Inc. (HOOK) 

NASDAQ
Market Cap
$19.5M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
693 of 960
Rank in Industry
387 of 550

Largest Insider Buys in Sector

HOOK Stock Price History Chart

HOOK Stock Performance

About HOOKIPA Pharma Inc.

HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16-positive …

Insider Activity of HOOKIPA Pharma Inc.

Over the last 12 months, insiders at HOOKIPA Pharma Inc. have bought $0 and sold $0 worth of HOOKIPA Pharma Inc. stock.

On average, over the past 5 years, insiders at HOOKIPA Pharma Inc. have bought $38,445 and sold $3.79M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 7,000 shares for transaction amount of $5,075 was made by Kandera Reinhard (Chief Financial Officer) on 2023‑08‑21.

List of Insider Buy and Sell Transactions, HOOKIPA Pharma Inc.

2023-08-21PurchaseChief Financial Officer
7,000
0.0091%
$0.72$5,075-7.79%
2023-08-16PurchaseChief Financial Officer
8,000
0.0103%
$0.71$5,712-5.67%
2023-07-11PurchaseChief Executive Officer
5,000
0.007%
$0.83$4,142-14.57%
2023-07-07PurchaseChief Executive Officer
5,000
0.0068%
$0.81$4,050-14.50%
2023-07-05PurchaseChief Executive Officer
5,000
0.0071%
$0.89$4,450-18.79%
2023-07-03PurchaseChief Executive Officer
5,000
0.0072%
$0.89$4,456-16.94%
2023-06-30PurchaseChief Financial Officer
12,000
0.0166%
$0.88$10,560-19.15%
2021-12-21SaleChief Medical Officer
14,949
0.0457%
$2.49$37,223-37.90%
2021-04-21Sale10 percent owner
328,620
0.9448%
$11.60$3.81M-58.05%
2021-03-29Sale10 percent owner
36,829
0.1234%
$13.67$503,570-54.96%
2021-03-26Sale10 percent owner
35,171
0.1167%
$13.69$481,642-54.91%
2021-03-25Sale10 percent owner
28,546
0.093%
$13.12$374,569-53.55%
2021-03-24Sale10 percent owner
52,690
0.1841%
$13.70$721,616-52.05%
2021-03-23Sale10 percent owner
40,000
0.1374%
$13.91$556,476-53.53%
2021-03-22Sale10 percent owner
40,534
0.1369%
$14.54$589,263-55.71%
2021-03-19Sale10 percent owner
166,230
0.5544%
$14.60$2.43M-56.39%
2020-12-17SaleChief Medical Officer
27,979
0.1031%
$11.74$328,343-20.23%
2020-12-16SaleChief Medical Officer
380
0.0014%
$11.70$4,446-18.84%
2020-10-02Sale10 percent owner
300
0.0011%
$10.00$3,000+13.55%
2020-09-15Sale10 percent owner
41,597
0.1949%
$12.61$524,477+5.48%

Insider Historical Profitability

<0.0001%
SOFINNOVA CAPITAL VI FCPR10 percent owner
3177574
32.9111%
$2.02112<0.0001%
Forbion Capital Fund II Cooperatief U.A.10 percent owner
2494173
25.8329%
$2.0210<0.0001%
BAKER BROS. ADVISORS LP
820729
8.5005%
$2.0210<0.0001%
Aldag JornChief Executive Officer
71952
0.7452%
$2.0240<0.0001%
Kandera ReinhardChief Financial Officer
43092
0.4463%
$2.0230<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Baker Bros Advisors LP$5.79B82.148.13M0%+$041.56
Artal Group S A$4.03B57.275.67M0%+$017.63
Tupelo Capital Management LLC$3.93B55.765.52M0%+$096.35
Ecor1 Capital Llc$3.27B46.444.6M0%+$022.96
Fidelity Investments$2.39B33.943.36M0%+$00.16
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.